| Symbol | ASMB |
|---|---|
| Name | ASSEMBLY BIOSCIENCES, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | TWO TOWER PLACE,7TH FLOOR, SOUTH SAN FRANCISCO, California, 94080, United States |
| Telephone | +1 833 509-4583 |
| Fax | — |
| — | |
| Website | https://www.assemblybio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The companys HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program. Additional info from NASDAQ: |
New Form DEFA14A - ASSEMBLY BIOSCIENCES, INC. <b>Filed:</b> 2026-04-22 <b>AccNo:</b> 0001193125-26-170508 <b>Size:</b> 2 MB
Read moreNew Form DEF 14A - ASSEMBLY BIOSCIENCES, INC. <b>Filed:</b> 2026-04-22 <b>AccNo:</b> 0001193125-26-170417 <b>Size:</b> 5 MB
Read moreBjorkquist Jeanette M 🟡 adjusted position in 6.2K shares of ASSEMBLY BIOSCIENCES, INC. (ASMB) at $27.49 Transaction Date: Mar 29, 2026 | Filing ID: 134669
Read moreWhite Nicole S 🟡 adjusted position in 25.8K shares of ASSEMBLY BIOSCIENCES, INC. (ASMB) at $27.49 Transaction Date: Mar 29, 2026 | Filing ID: 134645
Read moreOkazaki Jason A 🟢 acquired 94.2K shares of ASSEMBLY BIOSCIENCES, INC. (ASMB) Transaction Date: Mar 29, 2026 | Filing ID: 134496
Read more(99% Neutral) ASSEMBLY BIOSCIENCES, INC. (ASMB) Announces Executive Changes
Read moreNew Form EFFECT - ASSEMBLY BIOSCIENCES, INC. <b>Filed:</b> 2026-03-27 <b>AccNo:</b> 9999999995-26-000970 <b>Size:</b> 1 KB
Read moreAssembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights
Read moreNew Form S-3 - ASSEMBLY BIOSCIENCES, INC. <b>Filed:</b> 2026-03-19 <b>AccNo:</b> 0001193125-26-116161 <b>Size:</b> 975 KB
Read moreNew Form S-8 - ASSEMBLY BIOSCIENCES, INC. <b>Filed:</b> 2026-03-19 <b>AccNo:</b> 0001193125-26-116132 <b>Size:</b> 186 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT04820686 | A Study Evaluating Treatment Regimens Containing Vebicorvir (ABI-H0731) in Part… | Phase2 | Chronic Hepatitis B | Terminated | 2021-05-07 | 2023-03-30 | ClinicalTrials.gov |
| NCT04781647 | A Study Evaluating ABI-H0731-containing Regimens in Chinese Participants With C… | Phase2 | Chronic Hepatitis B | Terminated | 2021-02-18 | 2022-12-02 | ClinicalTrials.gov |
| NCT04271592 | A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABI-H3733 in He… | Phase1 | Chronic Hepatitis B | Completed | 2020-05-17 | 2021-01-14 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Quality Improvement | BEHAVIORAL | Preclinical | Type 2 Diabetes Mellitus | COMPLETED | NCT02234973 |